Related Experiment Video

Updated: Jul 6, 2026

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension
05:57

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension

Published on: May 17, 2024

Effect of pharmacological treatments for diabetes on homocysteine

Sunil Asnani1, Emily Chan, S N Murthy

  • 1Department of Medicine, Section of Endocrinology, Tulane University Health Sciences Center, New Orleans, Louisiana.

Metabolic Syndrome and Related Disorders
|March 29, 2008
PubMed

Insights

Hyperhomocysteinemia, high homocysteine levels, is linked to cardiovascular disease (CVD) risk in diabetes. Medications and vitamin treatments impact homocysteine, influencing CVD risk in type 2 diabetes mellitus and metabolic syndrome.

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Pharmacology

Background:

  • Hyperhomocysteinemia is a known risk factor for cardiovascular disease (CVD).
  • Its association with diabetes mellitus is complex, potentially explaining unexplained CVD risk in diabetic patients.
  • Homocysteine metabolism is influenced by genetic, demographic, nutritional, and hormonal factors, impacting atherosclerosis and CVD.

Purpose of the Study:

  • To review the effects of medications used in managing type 2 diabetes mellitus and metabolic syndrome on homocysteine metabolism.
  • To explore how these medications influence cardiovascular disease risk through homocysteine pathways.
  • To discuss the role of vitamin treatment in managing hyperhomocysteinemia and its potential impact on cardiovascular outcomes.

Main Methods:

  • Literature review of studies examining medication effects on homocysteine levels.
  • Analysis of the interplay between homocysteine metabolism, diabetes, metabolic syndrome, and cardiovascular risk factors.
  • Discussion of pharmacological and nutritional interventions affecting homocysteine concentrations.

Main Results:

  • Certain medications used for diabetes and metabolic syndrome can alter homocysteine metabolism, either increasing or decreasing plasma homocysteine levels.
  • Renal function changes and drug interactions significantly affect homocysteine levels.
  • Vitamin treatment for hyperhomocysteinemia can lower homocysteine concentrations and counteract some drug-induced effects.

Conclusions:

  • Medications for type 2 diabetes mellitus and metabolic syndrome have a complex relationship with homocysteine metabolism and CVD risk.
  • Understanding these interactions is crucial for managing cardiovascular risk in diabetic patients.
  • Further research is needed on the cardiovascular outcome effects of treating hyperhomocysteinemia in this population.

More Related Videos

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...